News and Trends 20 Oct 2017 Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene …of new, targeted therapies. PTEN is a known tumour suppressor gene, meaning it keeps cell growth under control and prevents cancer. It manages this by regulating the levels of phosphatidylinositol-3,4,5-trisphosphate… October 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 Encouraging results from respiratory diseases vaccine trial …IVX-121 has demonstrated robust immunological response to respiratory syncytial virus (RSV) in both young and older adult groups. The vaccine was generally tolerated with no vaccine-related serious adverse events (SAEs)…. June 29, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Dec 2022 Sibylla Biotech: how physicists met biologists to discover new drugs …events. With conventional molecular dynamics, this simply cannot be done on any existing computers or even those in development, for large and biologically relevant proteins. Our methods overcome this problem… December 14, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial …also associated with a high risk of cardiovascular events, contributing to a 20-25% risk of mortality within one year of diagnosis. There are currently limited treatment options for CLI but… January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2016 How did we grow from 0 to 40,000 Monthly Visitors in 18 Months? …What’s better than events to create a long-term relationship with your readers? The first edition of our event was a great success, and we are already preparing the next one… June 23, 2016 - 7 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2022 Growing hub Lithuania ready to welcome biotech sector to EFIB’22 On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for Industrial Biotechnology & the Bioeconomy 2022 (EFIB’22). EFIB, one of Europe’s top biotech events, will… October 6, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 Aeglea BioTherapeutics’ arginine 1 deficiency treatment gets EMA ok …mobility. In the PEACE study, most treatment-emergent adverse events were mild or moderate in severity and there were no discontinuations due to treatment-emergent adverse events. The EMA has granted pegzilarginase… August 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2024 Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration …discoveries into clinical successes. Recent events, such as the $688 million merger between Recursion Pharmaceuticals and Exscientia, two of the most important players in the field, have brought the industry’s… September 2, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Apr 2025 HIV innovation: Six companies developing new treatments in 2025 …trial met its primary endpoint, with the candidate being generally safe and well-tolerated among participants. No serious adverse events were observed, and only mild adverse events related to the therapy… April 16, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2019 CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders …few serious adverse events including sepsis and pneumonia, but they subsequently recovered and these events were not linked to the therapy. Beta-thalassemia and sickle cell disease are life-threatening inherited disorders…. November 19, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Astellas, Seagen and Merck give details on urothelial cancer treatment …duration of response (DOR) per BICR was not reached. All-grade treatment-related adverse events (TRAEs) of special interest for enfortumab vedotin in combination with pembrolizumab were skin reactions (67.1%), peripheral neuropathy… September 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 3 Mar 2023 Interview: how has the first gene therapy for hemophilia B transformed research? …a clinical setting, Hemgenix continues to be generally well-tolerated with no serious treatment-related adverse events (AEs). In terms of safety: there were no treatment related serious AEs in the pivotal… March 3, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email